Jefferies London 2026: The phase 3 OPERA-01study of Olema's CERAN + SERD, palazestrant, is setting up to be one of biotech's key readouts and is quickly approaching and scheduled to read in 1Q27
From BiotechTV - News · 00:11:42
Show by BiotechTV
CEO Sean Bohen reminds us of the mechanism and the design of this monotherapy study, which is in the 2/3 line ER+/HER2 metastatic breast cancer setting. He also discusses why he believes the OPERA-02 study in 2nd line in combo with a CDK 4/6 can succeed where a competitor failed earlier this year.
More episodes of BiotechTV - News
More episodes
- Jefferies London 2026: Zealand Pharma CEO Adam Steensberg gives an update on the company's amylin program and comments on recent data from its Boehringer partnered glucagon/GLP-1
- Jefferies London: When Celgene's powerhouse myeloma treatments emerged, it wasn't known that they were protein degraders. With today's advances in science, C4 aims to have a best in class degrader
- Jefferies London 2026: APOL1-mediated kidney disease affects over 1 million people in the United States - Maze Therapeutics hopes to deliver a solution
- Jefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3
- Jefferies London 2026: Erasca is racing to be the next big story in the RAS space (in both pancreatic and lung) and believes it may have a best in class asset with high potency
- Jefferies London 2026: With two FDA filings under review and other programs in late stage, Praxis is in a pivotal moment - CEO Marcio Souza updates us on all the moving pieces
- Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them
- Jefferies London 2026: Generate Biomedicines' CEO Mike Nally describes the rationale behind a recent CAR-T deal with Anthropic, updates us on the company's TSLP, and more
- Jefferies London 2026: Valneva CEO Thomas Lingelbach shares an update on the status of the company's Lyme disease program (partnered with Pfizer) and more pipeline projects
- Jefferies London 2026: Protagonist Therapeutics' CEO Dinesh Patel discusses the launch of ICOTYDE, and the company's pipeline, which is well funded now due to commercial success
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.